
Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic Study for Ulcerative Colitis
Shots: The P-IIIb VARSITY study involves assessing of Entyvio (vedolizumab, IV) vs Humira (adalimumab, SC) in 769 patients (anti-TNFα-naïve patients & anti-TNFα-experienced patients)
[Read More...]